Nachrichten zur Esperion Therapeutics Aktie

All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy

Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…

Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by…

Esperion Therapeutics (ESPR) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion: Early Commercial Success Supports A Buy At These Prices

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Has A Low Bar To Climb To Warrant Its Present Valuation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., May 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 15,…

Esperion Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics Inc (ESPR) Q1 2020 Earnings Call Transcript

ESPR earnings call for the period ending March 31, 2020....…

Esperion Therapeutics (ESPR) CEO Tim Mayleben on Q1 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics EPS beats by $0.49, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion to Report First Quarter 2020 Financial Results May 6, 2020

ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first…

Esperion out-licenses bempedoic acid meds in Japan to Otsuka

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Tablets in Japan

- Esperion to Receive $60 Million Upfront Payment -...…

Esperions Cholesterol Drugs Receive Approval in Europe

Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe....…

Esperions Nustendi OKd in Europe

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces European Commission Approval of the NUSTENDI (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

- First Non-Statin, LDL-C Lowering Combination Medicine Ever Approved in Europe -...…

Esperion Announces European Commission Approval of the NILEMDO (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

- First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients -...…

Esperion launches cholesterol med bempedoic acid in U.S.

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces Commercial Availability of the NEXLETOL (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

- First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a…

Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound-

Esperion Therapeutics (ESPR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Esperion Announces Three Data Presentations of the NEXLETOL (bempedoic acid) Tablet and the NEXLIZET (bempedoic acid and ezetimibe) Tablet at the American College of Cardiologys 69th Annual Scientific Session Together with World Congress of Ca

ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from…

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Card

ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from…

Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors

ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan…

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 26,…

Esperion to Participate in Upcoming Investor Conferences

ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that the company will participate…

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 16.61% and 1.66%, respectively, for the quarter ended December 2019. Do…

Esperion Therapeutics, Inc. 2019 Q4 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics down 12% premarket on Q4 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperions Lipid-Lowering Adjunctive Combo Therapy

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks…

Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results

ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and…

Esperion Announces FDA Approval of the NEXLIZET (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

- NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins -- First Non-Statin,…

Esperion Therapeutics: The Path After FDA Approval

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperions Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA Approves Esperion Therapeutics New Cholesterol Drug

Millions of patients who dont respond well enough to statins now have another affordable alternative....…

UPDATE 2-Esperion says cholesterol drug gets U.S. approval; eyes $10 per pill pricing

Esperion Therapeutics Inc said on Friday that U.S. health regulators approved its cholesterol-lowering drug, making it the first non-statin treatment to be cleared…

UPDATE 1-Esperions cholesterol drug gets U.S. approval; to be priced at $10 per pill

The U.S Food and Drug Administration approved Esperion Therapeutics Incs cholesterol-lowering drug as an add-on treatment to commonly used statins, the agency said…

Esperion Announces FDA Approval of NEXLETOL (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

- First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients -- NEXLETOL Lowers…

Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

- Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a…